ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended December 31, 2021
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0550 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer
Alembic Pharma gets tentative USFDA approval for depressive disorder drug
The tentative approval granted by the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Vortioxetine tablets of strengths in 5 mg, 10 mg, 15 mg and 20 mg, the company said in a statement. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Alembic Pharma gets USFDA nod for generic drug to treat Parkinson's disease
Alembic Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic Entacapone tablets indicated for patients with Parkinson's disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Entacapone tablets is for strength of 200 mg, the company said in a regulatory filing. It is therapeutically equivalent to the reference listed drug product (RLD) Comtan tablets, 200 mg, of Orion Corporation. Entacapone tablets are indicated as an adjunct to other medications, levodopa and carbidopa, to treat end-of-dose "wearing-off" in patients with Parkinson's disease. Citing IQVIA data, Alembic said Entacapone tablets 200 mg have an estimated market size of USD 10.5 million for 12 months ended September 2021. In the ongoing fiscal so far, the company said it has received 17 approvals (13 final approvals and 4 tentative approvals) and a cumulative total of 156 ANDA approvals (136 final .. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Entacapone Tablets USP, 200 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Alembic Pharma share price rises nearly 3% on USFDA approval for doxycycline
Doxycycline hyclate delayed-release tablets are indicated to reduce the development of drug-resistant bacteria ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). The details are provided in the attached letter. We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.